Jo Varshney News Today

Earlier this week, Charles River Laboratories International, Inc. revealed its Alternative Methods Advancement Project (AMAP), which it said is a strong initiative aimed at changing drug discovery and development by exploring alternatives to animal testing.

In an overwhelming response to the news that SimBioSys and General Inception had joined forces to use advanced AI and biophysical modeling, to gain deeper insights into tumor biology, the industry has spoken.

VeriSIM Life, a health care technology company, utilizes AI to forecast drug candidates' clinical success, accelerating development and reducing costs. Founder and CEO, Jo Varshney, discusses successful applications, challenges, privacy standards, and advice for leveraging AI in health care operations.

Jo Varshney, DVM, PhD, the founder of VeriSIM Life, shares her journey to her current position and the role of courage in it.

New AI-enabled, integrated workflow provides pharma and biotech companies with comprehensive R&D insights to help minimize late-stage failures during clinical trials LONDON, Dec. 5, 2023 /CNW/ -- Clarivate Plc

/PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world,...

Although AI’s presence on the public stage has become more prevalent in just the past year, it has been used in the medical field for more than four decades.

AI-driven technology developed by VeriSIM Life accelerates drug development and reduces the need for animal testing by analyzing pharmaceuticals before human trials.

/PRNewswire/ -- VeriSIM Life (VeriSIM) www.verisimlife.com, the leading artificial intelligence (AI)-enabled, unique R&D decisions de-risker for breakthrough...

VeriSIM Life eliminates waste and inaccuracy, accelerates preclinical development, and lowers costs and risks when converting drug candidates to clinical trials, and brings life-saving drugs